Health
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05,
About this update from Neumora Therapeutics, Inc.
[{"type":"image","alt":"Neumora Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Neumora Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_ktBLath.hAycAMjdGu3YQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTc5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0","width":183,"height":40}},"lazy":false},{"type":"text","content":"NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect ","length":108,"tagName":"p"},{"type":"text","content":"NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety","length":126,"tagName":"p"},{"type":"text","content":"NMRA-511 demonstrated a favorable tolerability and safety profile ","length":65,"tagName":"p"},{"type":"text","content":"Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026","length":119,"tagName":"p"},{"type":"text","content":"Company to host conference call today at 8:00 am ET","length":51,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer’s disease (AD) agitation. NMRA-511, an oral, highly potent, brain-penetrant and selective antagonist of the vasopressin 1a receptor (V1aR) met the goal of the Phase 1b study, demonstrating a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable tolerability and safety profile with no reports of somnolence or sedation.","length":768,"tagName":"p"},{"type":"text","content":"“The goal of this signal-seeking study was to investigate the clinical potential of NMRA-511 in AD agitation and to identify a clinical effect size to inform further development. It has achieved that goal, demonstrating a clinically meaningful and ro...